
A medication already approved for excessive daytime sleepiness may help ease attention-deficit/hyperactivity disorder (ADHD) symptoms in adults who aren’t getting relief from available treatments, according to a small pilot study. Solriamfetol is a nonstimulant drug that is approved for sleepiness caused by narcolepsy (sudden sleep attacks) and obstructive sleep apnea (marked by breathing lapses during sleep). “The pilot study is very promising, but more research is needed before this medication can be recommended or approved for adults with ADHD,” said study author Dr. Craig Surman. He is the director of the clinical and research program for adult ADHD at Massachusetts General Hospital and an associate professor of psychiatry at Harvard Medical School, in Boston. For the study, 60 adults with ADHD took 75 or 150 milligrams of solriamfetol or a placebo for six weeks. They were interviewed about ADHD symptoms throughout the study and filled out self-reports. By the end of the study, more folks taking solriamfetol showed improvements in ADHD symptoms than those who took the placebo. The drug’s makers, Jazz Pharmaceuticals and Axsome Therapeutics, funded the study. In the United States, as many as 10 million adults have ADHD. They may have difficulty paying attention, impulsiveness and trouble with executive functions such as analyzing, organizing and planning — problems that can hinder success at school, work or in personal relationships, according to Children… read on > read on >